Dr. Grippin completed his medical and doctoral training at the University of Florida, where he developed a personalized mRNA-nanoparticle platform that is currently in first-in-human clinical trials for treatment of brain tumors. He has published several peer-reviewed papers, including in ACS Nano and Nanoletters. Dr. Grippin’s research accomplishments have been recognized by several awards and scholarships, including the Ruth L. Kirschstein National Research Service Award and induction into the University of Florida Hall of Fame. His research interest is in the development and translation of novel cancer immunotherapy agents.